Andrew has a long track record of finding innovative solutions for dispute and licensing challenges for a wide range of technology companies in the chemical, biotech, and information technology industries.
Andrew represents a wide variety of technology and media companies in intellectual property disputes and licensing, joint development, and commercial transactions. He focuses his patent dispute practice on inter partes review (IPR) proceedings before the PTAB, trials and arbitrations relating to pharmaceuticals and biotechnology, biosimilars, medical devices, mechanical inventions, and software. He is experienced in the full array of issues that arise in connection with intellectual property disputes, including patent, trademark, and copyright protection and infringement; International Trade Commission proceedings; antitrust issues; and trade secret and trade dress protection and disputes. He focuses his transactional practice on national and international commercial, sale, and licensing deals in the biotech and information technology fields.
Andrew is highly experienced in IPR practice before the PTAB, and has served as litigation counsel in more than 40 IPR proceedings. He and his team have successfully represented both patent owners and petitioners across a wide variety of technology areas. His team is also well-versed in other proceedings before the Patent Office, including ex parte reexaminations, reissues, supplemental examinations, derivation proceedings, and interferences.
Additionally, Andrew has an active abbreviated new drug application (ANDA) patent litigation practice. He has served as lead counsel in more than a dozen ANDA litigations in the U.S. and has coordinated international pharmaceutical patent enforcement strategies in Europe, Canada, India, Japan, New Zealand, and Australia. Andrew has also counselled numerous clients on litigation strategies relating to biosimilars. Many of these matters have involved billion-dollar drug products, and he has worked with internationally renowned experts, conducted Markman hearings and trials, and consulted with clients on antitrust, biosimilar patent dance, FDA, and settlement strategies.
Andrew has also handled many copyright, trademark, and trade secret disputes. He has represented dozens of technology, media, franchise, and distribution companies in a wide range of areas, including business formation, regulatory and disclosure practice, dispute resolution, litigation, and arbitration work. Andrew has represented numerous national technology and franchise companies in dozens of litigations and arbitrations on issues such as trademark/copyright infringement, trade secret misappropriation, sales fraud, distribution disputes, encroachment, implied covenant claims, and antitrust disputes.
Andrew is practice group leader for Health Sciences Intellectual Property.
PTAB Proceedings – IPRs
Patent Litigations
Copyright, Trademark, and Trade Secret Litigations
Representative matters may include engagements before joining Troutman Pepper.
Speaking Engagements
04.23.24
Arizona State Bar CLE - Patent Post-Issuance Proceedings at the USPTO
Podcasts
02.15.24
Behaving Badly: OpenSky v. VLSI and Sanctions at the PTAB
Articles + Publications
10.26.23
The Murky World of IP Protection for Gene-Edited Plants
Podcasts
10.25.23
USPTO Director Review
Firm News
09.22.23
Troutman Pepper Partner Andrew Zappia Named to The Daily Record's Power List for Intellectual Property 2023
Podcasts
07.11.23
Disputing Patent-Eligible Subject Matter in PGRs and IPRs